Related stories
Pfizer Raises 2026 Forecasts as Third-Quarter Results Are Driven by Eliquis, Cancer Drugs
Pfizer raised its 2026 forecasts as Eliquis and cancer drugs drove third-quarter results.
M impact | EARNINGS | Nov 03, 2026, 05:13 PM UTC
BNP Paribas Forecasts CET1 Ratio Above 13% by End-2026
BNP Paribas forecasts its CET1 ratio will exceed 13% at the end of 2026.
M impact | EARNINGS | Nov 03, 2026, 05:06 PM UTC
M6 Reports Quarterly EBITA Up 4.2% to EUR 39 Million
M6 said quarterly EBITA rose 4.2% to EUR 39 million, while its net cash position increased by EUR 166.7 million.
M impact | EARNINGS | Nov 03, 2026, 05:06 PM UTC
Magnificent 7 Profit Growth Trails Rest of S&P 500 in Q3
FactSet says profit growth for the Magnificent 7 lagged the rest of the S&P 500 in the third quarter.
M impact | EARNINGS | Nov 03, 2026, 05:03 PM UTC
M6 Reports EBITA Growth and Higher Net Cash
M6 reported growth in EBITA and an increase in net cash over the quarter.
M impact | EARNINGS | Nov 03, 2026, 05:03 PM UTC
Omer-Decugis & Cie Expects Lower EBITDA Margin in 2025/26
L impact | EARNINGS | Nov 03, 2026, 05:02 PM UTC